244 related articles for article (PubMed ID: 17414950)
21. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
22. Macrophages and their products in rheumatoid arthritis.
Szekanecz Z; Koch AE
Curr Opin Rheumatol; 2007 May; 19(3):289-95. PubMed ID: 17414958
[TBL] [Abstract][Full Text] [Related]
23. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production.
Abdollahi-Roodsaz S; Joosten LA; Helsen MM; Walgreen B; van Lent PL; van den Bersselaar LA; Koenders MI; van den Berg WB
Arthritis Rheum; 2008 Dec; 58(12):3753-64. PubMed ID: 19035506
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges.
Vandenbroeck K; Alloza I; Gadina M; Matthys P
J Pharm Pharmacol; 2004 Feb; 56(2):145-60. PubMed ID: 15005873
[TBL] [Abstract][Full Text] [Related]
25. Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.
Liu FL; Chen CH; Chu SJ; Chen JH; Lai JH; Sytwu HK; Chang DM
Rheumatology (Oxford); 2007 Aug; 46(8):1266-73. PubMed ID: 17569750
[TBL] [Abstract][Full Text] [Related]
26. Factors underlying chronic inflammation in rheumatoid arthritis.
Wong SH; Lord JM
Arch Immunol Ther Exp (Warsz); 2004; 52(6):379-88. PubMed ID: 15577739
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases.
McInnes IB; Gracie JA
Curr Opin Pharmacol; 2004 Aug; 4(4):392-7. PubMed ID: 15251134
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 6: from bench to bedside.
Nishimoto N; Kishimoto T
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
[TBL] [Abstract][Full Text] [Related]
29. [Cytokines in rheumatoid arthritis. II. Anti-inflammatory cytokines].
Klimiuk PA; Sierakowski S
Pol Merkur Lekarski; 2001 Dec; 11(66):514-6. PubMed ID: 11899851
[TBL] [Abstract][Full Text] [Related]
30. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.
Brentano F; Schorr O; Ospelt C; Stanczyk J; Gay RE; Gay S; Kyburz D
Arthritis Rheum; 2007 Sep; 56(9):2829-39. PubMed ID: 17763446
[TBL] [Abstract][Full Text] [Related]
31. Review: Immune cells and mediators of inflammatory arthritis.
Schett G
Autoimmunity; 2008 Apr; 41(3):224-9. PubMed ID: 18365836
[TBL] [Abstract][Full Text] [Related]
32. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis.
Vandooren B; Noordenbos T; Ambarus C; Krausz S; Cantaert T; Yeremenko N; Boumans M; Lutter R; Tak PP; Baeten D
Arthritis Rheum; 2009 Apr; 60(4):966-75. PubMed ID: 19333931
[TBL] [Abstract][Full Text] [Related]
33. Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation.
Sakurai N; Kuroiwa T; Ikeuchi H; Hiramatsu N; Maeshima A; Kaneko Y; Hiromura K; Nojima Y
Rheumatology (Oxford); 2008 Jun; 47(6):815-20. PubMed ID: 18397956
[TBL] [Abstract][Full Text] [Related]
34. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis.
Sheibanie AF; Khayrullina T; Safadi FF; Ganea D
Arthritis Rheum; 2007 Aug; 56(8):2608-19. PubMed ID: 17665454
[TBL] [Abstract][Full Text] [Related]
35. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
[TBL] [Abstract][Full Text] [Related]
36. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy.
Singh R; Aggarwal A; Misra R
J Rheumatol; 2007 Nov; 34(11):2285-90. PubMed ID: 17937463
[TBL] [Abstract][Full Text] [Related]
37. Cytokines as therapeutic targets: advances and limitations.
Scheinecker C; Redlich K; Smolen JS
Immunity; 2008 Apr; 28(4):440-4. PubMed ID: 18400186
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-21 as a new therapeutic target for immune-mediated diseases.
Monteleone G; Pallone F; Macdonald TT
Trends Pharmacol Sci; 2009 Aug; 30(8):441-7. PubMed ID: 19616319
[TBL] [Abstract][Full Text] [Related]
39. Th17 cytokines and their emerging roles in inflammation and autoimmunity.
Fouser LA; Wright JF; Dunussi-Joannopoulos K; Collins M
Immunol Rev; 2008 Dec; 226():87-102. PubMed ID: 19161418
[TBL] [Abstract][Full Text] [Related]
40. CCL20 produced in the cytokine network of rheumatoid arthritis recruits CCR6+ mononuclear cells and enhances the production of IL-6.
Tanida S; Yoshitomi H; Nishitani K; Ishikawa M; Kitaori T; Ito H; Nakamura T
Cytokine; 2009 Aug; 47(2):112-8. PubMed ID: 19535263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
